Estimated costs of managing treatment-related adverse events (TRAEs) of nivolumab (nivo) and docetaxel (doc) in the CheckMate 017 and CheckMate 057 phase III non-small cell lung cancer (NSCLC) trials

被引：1

作者：

Venkatachalam, Meena

Stenehjem, David D.

Pietri, Guilhem

Penrod, John R.

Korytowsky, Beata

机构：

[1] Parexel, Waltham, MA USA

[2] Univ Utah, Coll Pharm, Dept Pharmacotherapy, Salt Lake City, UT 84112 USA

[3] Bristol Myers Squibb, Princeton, NJ USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期

关键词：

D O I：

10.1200/JCO.2016.34.15_suppl.6617

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

6617

引用

页数：4

共 50 条

[31] Is Nivolumab Safe and Effective in Elderly and PS2 Patients with Non-Small Cell Lung Cancer (NSCLC)? Results of CheckMate 153 [J].

Spigel, David ;

Schwartzberg, Lee ;

Waterhouse, David ;

Chandler, Jason ;

Hussein, Maen ;

Jotte, Robert ;

Stepanski, Edward ;

Mccleod, Michael ;

Page, Ray ;

Sen, Rohini ;

Mcdonald, Jeffrey ;

Bennett, Kelly ;

Korytowsky, Beata ;

Aanur, Nivedita ;

Reynolds, Craig .

JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) :S1287-S1288

[32] Nivolumab (NIVO) plus ipilimumab (IPI) with two cycles of chemotherapy (chemo) in first-line metastatic non-small cell lung cancer (NSCLC): CheckMate 568 Part 2. [J].

Gainor, Justin F. ;

Schneider, Jeffrey Gary ;

Gutierrez, Martin ;

Orcutt, James Michael ;

Finley, Gene Grant ;

Otterson, Gregory Alan ;

Rybkin, Igor I. ;

Reddy, Pavan S. ;

Horn, Leora ;

Brahmer, Julie R. ;

Bastos, Bruno R. ;

Awad, Mark M. ;

Hellmann, Matthew David ;

Ramalingam, Suresh S. ;

Ready, Neal E. ;

Spigel, David R. ;

Kasinathan, Ravi S. ;

Dorange, Cecile ;

Borghaei, Hossein .

JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)

[33] Nivolumab (NIVO) plus platinum-doublet chemotherapy (chemo) versus chemo as neoadjuvant treatment for resectable non-small cell lung cancer (NSCLC): Health-related quality of life (HRQoL) outcomes from CheckMate 816 [J].

Felip, E. ;

Wang, C. ;

Ciuleanu, T-E. ;

Saylors, G. ;

Tanaka, F. ;

Chen, K-N. ;

Ito, H. ;

Girard, N. ;

Lu, S. ;

Provencio Pulla, M. ;

Mitsudomi, T. ;

Awad, M. ;

Forde, P. M. ;

Lawrance, R. ;

Taylor, F. ;

Worthy, G. ;

Blum, S. I. ;

Vo, L. ;

Cai, J. L. ;

Spicer, J. .

ANNALS OF ONCOLOGY, 2022, 33 (07) :S973-S974

[34] Costs of Adverse Events (AE) Associated with Cancer Therapies in Non-Small Cell Lung Cancer (NSCLC) in France [J].

Chouaid, Christos ;

Loirat, Delphine ;

Godard, Chloe ;

Clay, Emilie ;

Millier, Aurelie ;

Levy-Bachelot, Laurie ;

Angevin, Eric .

JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) :S693-S693

[35] Surgical outcomes from the phase 3 CheckMate 816 trial: Nivolumab (NIVO) plus platinum-doublet chemotherapy (chemo) vs chemo alone as neoadjuvant treatment for patients with resectable non-small cell lung cancer (NSCLC). [J].

Spicer, Jonathan ;

Wang, Changli ;

Tanaka, Fumihiro ;

Saylors, Gene Brian ;

Chen, Ke-Neng ;

Liberman, Moishe ;

Vokes, Everett E. ;

Girard, Nicolas ;

Lu, Shun ;

Provencio, Mariano ;

Mitsudomi, Tetsuya ;

Awad, Mark M. ;

Felip, Enriqueta ;

Forde, Patrick M. ;

Swanson, Scott ;

Brahmer, Julie R. ;

Kerr, Keith ;

Dorange, Cecile ;

Cai, Junliang ;

Broderick, Stephen .

JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)

[36] Nivolumab (NIVO) plus platinum-doublet chemotherapy (chemo) vs chemo as neoadjuvant treatment (tx) for resectable (IB-IIIA) non-small cell lung cancer (NSCLC) in the phase 3 CheckMate 816 trial. [J].

Forde, Patrick M. ;

Spicer, Jonathan ;

Lu, Shun ;

Provencio, Mariano ;

Mitsudomi, Tetsuya ;

Awad, Mark M. ;

Felip, Enriqueta ;

Broderick, Stephen ;

Brahmer, Julie ;

Swanson, Scott J. ;

Kerr, Keith ;

Wang, Changli ;

Saylors, Gene B. ;

Tanaka, Fumihiro ;

Ito, Hiroyuki ;

Chen, Ke-Neng ;

Dorange, Cecile ;

Cai, Junliang ;

Fiore, Joseph ;

Girard, Nicholas .

CANCER RESEARCH, 2021, 81 (13)

[37] Incidence, severity, and etiology of treatment-related lymphopenia in patients with stage III non-small cell lung cancer (NSCLC). [J].

Campian, Jian Li ;

Ye, Xiaobu ;

Hooker, Craig ;

Brock, Malcolm ;

Grossman, Stuart A. .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)

[38] CheckMate 73L: A phase III study comparing nivolumab (NIVO) plus concurrent chemoradiotherapy (CCRT) followed by NIVO ± ipilimumab (IPI) versus CCRT followed by durvalumab (DURV) for previously untreated, locally advanced (LA) stage III non-small cell lung cancer (NSCLC) [J].

De Ruysscher, D. ;

Ramalingam, S. S. ;

Urbanic, J. ;

Gerber, D. E. ;

Tan, D. S. W. ;

Cai, J. ;

Li, A. ;

Peters, S. .

ANNALS OF ONCOLOGY, 2020, 31 :S810-S810

[39] Immune-Related Adverse Events and Their Effect on Outcomes in Patients (pts) with Non-Small Cell Lung Cancer (NSCLC) Treated with Nivolumab [J].

Kothari, Shawn ;

Bagley, Stephen ;

Aggarwal, Charu ;

Baum, Joshua ;

Alley, Evan ;

Evans, Tracey ;

Kosteva, John ;

Ciunci, Christine ;

Thompson, Jeffrey ;

Stonehouse-Lee, Susan ;

Sherry, Victoria ;

Gilbert, Elizabeth ;

Eaby-Sandy, Beth ;

Mutale, Faith ;

Dilullo, Gloria ;

Cohen, Roger ;

Vachani, Anil ;

Langer, Corey .

JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) :S1290-S1290

[40] Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non-Small Cell Lung Cancer [J].

Haratani, Koji ;

Hayashi, Hidetoshi ;

Chiba, Yasutaka ;

Kudo, Keita ;

Yonesaka, Kimio ;

Kato, Ryoji ;

Kaneda, Hiroyasu ;

Hasegawa, Yoshikazu ;

Tanaka, Kaoru ;

Takeda, Masayuki ;

Nakagawa, Kazuhiko .

JAMA ONCOLOGY, 2018, 4 (03) :374-378

← 1 2 3 4 5 →